Literature DB >> 20503417

Overcoming radiation resistance in inflammatory breast cancer.

Wendy A Woodward1, Bisrat G Debeb, Wei Xu, Thomas A Buchholz.   

Abstract

The clinical-pathological features of inflammatory breast cancer include enrichment of factors that have been previously associated with radioresistant disease, including negative hormone receptor status and a phenotype enriched for relatively radioresistant breast cancer stem/progenitor cells. The risks and benefits of accelerated postmastectomy radiation treatment regimens in the multimodality management of inflammatory breast cancer were reviewed at the first International Inflammatory Breast Cancer Conference at The University of Texas M. D. Anderson Cancer Center. The biological basis for radiation resistance and strategies to radiosensitize these tumors were also presented. The prevalent basal phenotype of inflammatory breast cancer makes it an ideal clinical model to examine stem cell hypotheses, which the authors believe can help guide future trials to continue making incremental progress against this aggressive disease. Copyright 2010 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20503417     DOI: 10.1002/cncr.25173

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

Review 1.  Inflammatory breast cancer: what we know and what we need to learn.

Authors:  Hideko Yamauchi; Wendy A Woodward; Vicente Valero; Ricardo H Alvarez; Anthony Lucci; Thomas A Buchholz; Takayuki Iwamoto; Savitri Krishnamurthy; Wei Yang; James M Reuben; Gabriel N Hortobágyi; Naoto T Ueno
Journal:  Oncologist       Date:  2012-05-14

2.  How do I treat inflammatory breast cancer?

Authors:  Della Makower; Joseph A Sparano
Journal:  Curr Treat Options Oncol       Date:  2013-03

3.  Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells.

Authors:  Bisrat G Debeb; Xiaomei Zhang; Savitri Krishnamurthy; Hui Gao; Evan Cohen; Li Li; Angel A Rodriguez; Melissa D Landis; Anthony Lucci; Naoto T Ueno; Fredika Robertson; Wei Xu; Lara Lacerda; Thomas A Buchholz; Massimo Cristofanilli; James M Reuben; Michael T Lewis; Wendy A Woodward
Journal:  Mol Cancer       Date:  2010-07-08       Impact factor: 27.401

4.  Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy.

Authors:  Chiaojung Jillian Tsai; Jing Li; Ana M Gonzalez-Angulo; Pamela K Allen; Wendy A Woodward; Naoto T Ueno; Anthony Lucci; Savitri Krishnamurthy; Yun Gong; Wei Yang; Massimo Cristofanilli; Vicente Valero; Thomas A Buchholz
Journal:  Am J Clin Oncol       Date:  2015-06       Impact factor: 2.339

5.  Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.

Authors:  Bisrat G Debeb; Evan N Cohen; Kimberly Boley; Erik M Freiter; Li Li; Fredika M Robertson; James M Reuben; Massimo Cristofanilli; Thomas A Buchholz; Wendy A Woodward
Journal:  Breast Cancer Res Treat       Date:  2012-05-01       Impact factor: 4.872

6.  Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.

Authors:  M S Eng; J Kaur; L Prasmickaite; B Ø Engesæter; A Weyergang; E Skarpen; K Berg; M G Rosenblum; G M Mælandsmo; A Høgset; S Ferrone; P K Selbo
Journal:  Photochem Photobiol Sci       Date:  2018-05-16       Impact factor: 3.982

7.  A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer.

Authors:  Wendy A Woodward; Penny Fang; Lisa Arriaga; Hui Gao; Evan N Cohen; James M Reuben; Vicente Valero; Huong Le-Petross; Lavinia P Middleton; Gildy V Babiera; Eric A Strom; Welela Tereffe; Karen Hoffman; Benjamin D Smith; Thomas A Buchholz; George H Perkins
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-05-03       Impact factor: 8.013

8.  Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines.

Authors:  Nandita Barnabas; Dalia Cohen
Journal:  Int J Breast Cancer       Date:  2013-01-16

9.  Differential effect of phosphorylation-defective survivin on radiation response in estrogen receptor-positive and -negative breast cancer.

Authors:  Bisrat G Debeb; Daniel L Smith; Li Li; Richard Larson; Wei Xu; Wendy A Woodward
Journal:  PLoS One       Date:  2015-03-12       Impact factor: 3.240

10.  EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.

Authors:  Bisrat G Debeb; Yun Gong; Rachel L Atkinson; Nour Sneige; Lei Huo; Ana Maria Gonzalez-Angulo; Mien-Chie Hung; Vicente Valero; Naoto T Ueno; Wendy A Woodward
Journal:  J Exp Clin Cancer Res       Date:  2014-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.